Recently, Sanogen announced that its second aging stem pre candidate drug SRN-901 in its pipeline has completed preliminary preclinical animal experiments. It is reported that SRN-901 was developed in collaboration with medical institutions such as Harvard University, Mayo Clinic, and Scripps Institute. It is also the technology source for the oral aging inhibitor Restorin (Ruituoling) released by Sinopharm Group's joint venture with Sinopharm at last year's CIIE. In order to develop this breakthrough product known as the "strongest anti-aging inhibitor", Sanogen spent a huge amount of money over several years conducting the most comprehensive and in-depth global anti-aging inhibitor efficacy evaluation to date, and compared more than ten of the most promising anti-aging inhibitors and various dosage forms using hundreds of mice. Dr. David Brown, a scientist involved in this project, revealed that the study was initiated in 2021 and covers various fields throughout the mouse lifespan over a period of more than three years, from lifespan length to physical function, blood indicators, to transcriptome analysis at the cellular and molecular levels, proteomics, metabolomics, and even machine learning modeling at the bioinformatics level. The data shows that starting from middle age in mice (equivalent to over 50 years old in humans), the remaining lifespan of the SRN-901 experimental group increased by more than 30%, surpassing the rapamycin control group under the same conditions; The physical fitness of elderly mice has increased from less than 20% in their youth to 50%, and the incidence of tumors has been reduced by half, both reaching the highest level of oral aging inhibitors currently available. In the 21st century, research and academic institutions led by the Massachusetts Institute of Technology, Harvard Medical School, and Mayo Clinic have made a series of major breakthroughs, such as the mTOR pathway inhibition technology that regulates aging and lifespan by controlling cell nutrition supply, the longevity protein Sirtuins activation technology that enhances DNA repair ability, NAD+enhancement and mitochondrial autophagy activation technology that maintains cell energy metabolism ability, and the targeted clearance (Sinolysis) technology for aging cells that maintains organ health. However, transforming these scientific research achievements into effective products is not something that a single academic institution can accomplish alone. The mature experience of professional original pharmaceutical companies in technology integration, clinical validation, and industrial collaboration is also indispensable. The effectiveness of a drug is closely related to the synthesis process, dosage form design, dosage formulation, and delivery and absorption technology of its various components, each of which requires long-term technical research and repeated verification. The "double ten law" of new drug development - that is, it takes more than 10 years and 1 billion dollars to successfully develop a new drug - is precisely derived from this. These thresholds also lead to significant therapeutic differences between generic drugs with similar components compared to original drugs - because original drug companies accumulate a large amount of non-public proprietary technology and know how during the research and development process, and generic drugs cannot obtain these key matching technology secrets, making the effects naturally difficult to compare with. It is reported that in the emerging field of aging intervention, Sanogen has established a large-scale multinational scientific research and industrial collaboration alliance in the field of aging medicine. Taking the development of SRN-901 as an example, its participants include 10 laboratories from 5 global research institutions, including Harvard University, Mayo Clinic, Scripps Institute, University of Pennsylvania, and Buck Institute. The clinical research was jointly conducted by two of the world's top ten clinical research organizations (CROs) - Charles River and WuXi AppTec. At the level of industrial cooperation, Sanogen has deeply cooperated with more than 20 technology suppliers across the United States, Europe, and Asia, and spent 5 years successfully overcoming a series of technical difficulties in synthesis process, dosage form design, delivery and absorption. At the same time, Sanogen and the two major original researchers of these technologies - Harvard University and Mayo Clinic - jointly established Sanogen Biosciences, obtaining exclusive global authorization for a series of core patents and technological secrets in the fields of aging inhibition and natural life extension from Harvard University and Mayo Medical Center. Currently, Sinopharm Group has established a joint venture with Sinopharm Sinogen to establish Sinopharm Sinogen Company. In addition to introducing advanced aging intervention products such as Ruituoling, which will be jointly developed by Sinogen and Harvard, Mayo, Scripps, etc. within this year, Sinopharm will also vigorously invest in local research and development of advanced aging intervention technologies. (Lai Xin She)